Eli Lilly & Company has asked a federal judge to block Mylan Pharmaceuticals Inc., Apotex Inc., and other generics makers from releasing their own versions of attention deficit hyperactivity disorder drug Strattera ® until a federal appeals court rules on the validity of the patent covering the treatment. In response to a ruling that the patent-in-suit is invalid due to lack of enablement, Lilly filed a motion Monday in the U.S. District Court for the District of New Jersey seeking a temporary injunction barring the seven remaining defendants in the infringement suit from launching generic versions of Strattera ® until the U.S. Court of Appeals for the Federal Circuit decides Lilly's appeal of the invalidity ruling. The motion, signed by Lilly attorney M. Andrew Holtman of Finnegan, also requests that if the injunction bid is denied, the court similarly enjoin the generic-drug makers while Lilly appeals the denial of the injunction to the Federal Circuit. Eli Lilly & Co. is represented by Finnegan.